European Respiratory Society Annual Congress 2013

European Respiratory Society
Annual Congress 2013
Abstract Number: 5100
Publication Number: P3090
Abstract Group: 1.4. Interventional Pulmonology
Keyword 1: Pleura Keyword 2: Lung cancer / Oncology Keyword 3: Thoracic oncology
Title: Medical thoracoscopy in the diagnosis and treatment of lung/pleural disease: Sharing an experience
of 1125 cases
Dr. Georgia 33143 Hardavella [email protected] MD 1, Dr. Dimitrios 33144 Zachilas
[email protected] MD 1, Dr. Georgia 33201 Doga [email protected] 1, Dr. Maria 33147 Dassiou
[email protected] MD 1, Dr. Stavros 33145 Malagaris [email protected] MD 1, Dr. Gerasimos 33146
Papavasileiou [email protected] MD 1 and Dr. Nikolaos 33148 Anastasiou [email protected]
MD 1. 1 Thoracic Surgery, General Oncology Hospital "Agioi Anargyroi", Kifissia, Athens, Greece, 14565 .
Body: Introduction:MT has substantially thrived over the last decade and has been a useful technique in the
hands of experienced chest physicians. Objective:To assess our 12-year experience(2000-2012)of our first
1125 MT cases in terms of clinical efficacy/patient outcome. Materials and methods:Retrospective review of
1125 MT patients&clinical follow up at 1, 6 and 12 months post procedure.We assessed diagnostic
efficacy,sensitivity,complications,recurrences,survival,clinical effectiveness(SPSS v12.0). Results:Patients
were 757 males and 368 females(mean age 69.7 years). 137/1125 had high risk comorbidities steming
them from more invasive procedures.All MTs were performed in the endoscopy suite under conscious
sedation(midazolam, fentanyl)and intercostal block(ropivacain)to diagnose+/-treat lung/pleural
diseases.Mean hospital stay: 2.1 days(range 0-4) for diagnostic and 3.4 days(range 1-15) for therapeutic
MT.The procedures were pleural biopsy 276/1125,talc pleurodesis 383/1125,pleural biopsy&talc pleurodesis
125/1125,lung biopsy(stappler device) 52/1125,empyema 264/1125, haemothorax 25/1125.Diagnosis was
obtained in 95% patients, palliation in 65%, clinical effictiveness with no recurrency at 12 months in 84%.
Sensitivity:88% for pleural and 99% for lung biopsies.Mortality:0.088%.No intraoperative or postoperative
complications were recorded. Conclusions:The assessment of our first 1125 MT showed increased
sensitivity,diagnostic and clinical efficacy with minimal hospital stay and morbidity.MT has been also safe
and efficient in patients unable to undergo more invasive procedures.MT can be a useful tool in the hands of
a skilled thoracic team ensuring optimal patient outcome.